Atrial Fibrillation - Part 1 - CB-Training & Emedit

Part 1 of a two-part program that provides an overview of current therapies for atrial fibrillation. These include anti-coagulation, rate control strategies, pharmacologic rhythm control, pacing therapy and catheter ablation.

N.B. This program was originaly produced for US healthcare workers.

ONLINE PROGRAM OBJECTIVES

Upon completion of this online program, the participant should be able:

>	To identify the appropriate strategies for anticoagulation in patients with atrial fibrillation and atrial flutter;
>	To understand the important relationship between the duration of anticoagulant therapy and degree of anticoagulation with coumadin and risk of/severity of thromboembolic complication in the setting of atrial fibrillation;
>	To identify the role and limitations of a rate control treatment strategy in patients with atrial fibrillation;
>	To identify the appropriate patients for and risks of pharmacologic rhythm control in patients with atrial fibrillation;
>	To identify important drug interactions, routes of excretion and side effects for drugs used in attempting to maintain sinus rhythm.

TIME

Approximately 1.5 hours

COST

£20

AUTHORS

Francis E. Marchlinski, M.D., F.A.C.C.

Dr. Frank E. Marchlinski is a Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia, PA. He is also the Director of Electrophysiology at the University of Pennsylvania Health System. Dr. Marchlinski received his medical degree from the University of Pennsylvania School of Medicine, and served his medical residency and cardiology fellowships at the Hospital of the University of Pennsylvania. He is board certified in internal medicine, cardiology and electrophysiology. Dr. Marchlinski has lectured and written extensively on the diagnosis and treatment of cardiac arrhythmias.

To find out more about this and future CBT and Emedit
e-learning opportunities, contact:
Jane Kennedy
Clinical Director
Tel: 01899 229 337
Email: jane.kennedy@cb-training.com

>Back to previous page

> Advertise with us